Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CASI Pharmaceuticals ( (CASI) ) has issued an update.
CASI Pharmaceuticals, Inc. said on February 19, 2026 that its board has appointed Dr. Wei-Wu He as executive chairman effective February 17, 2026, with former non-executive chairman James Huang stepping down from that role but remaining on the board. The board also resolved to streamline the company’s U.S. branches, personnel and related activities to address commercial and listing compliance challenges and to concentrate resources on strengthening its core business operations.
The leadership change and operational refocus underscore CASI’s response to pressure around its Nasdaq listing status and commercial performance. These moves are intended to tighten cost structures, sharpen strategic execution around its lead asset CID-103 and may signal a shift toward greater centralization of decision-making and capital allocation for shareholders and other stakeholders.
The most recent analyst rating on (CASI) stock is a Hold with a $0.96 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
Spark’s Take on CASI Stock
According to Spark, TipRanks’ AI Analyst, CASI is a Neutral.
The score is primarily weighed down by poor financial performance (declining revenue, ongoing losses, negative and worsening free cash flow, and very high leverage). Technicals are somewhat improved in the short term but remain weak versus longer-term trend levels, while valuation is difficult to support due to negative earnings and no dividend yield data.
To see Spark’s full report on CASI stock, click here.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company listed on Nasdaq that focuses on developing CID-103, an anti-CD38 monoclonal antibody. The company targets indications including organ transplant rejection and autoimmune diseases, with operations spanning China and the United States.
Average Trading Volume: 37,024
Technical Sentiment Signal: Sell
Current Market Cap: $12.77M
For detailed information about CASI stock, go to TipRanks’ Stock Analysis page.